Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
FMT trials MIMic (NCT03772899) is a phase 1 trial 23 enrolling patients with unresectable or metastatic cutaneous melanoma measurable disease as per RECIST v.1.1 criteria with no previous anti-PD-1 treatment who underwent FMT and were treated with anti-PD-1 (either pembrolizumab or nivolumab)
Di Sabatino 2005)
p -value 0.6677]) was not associated with a significant increased risk of abdominal discomfort, as shown in Fig
ASC Ref No
US$ 22.00
US$ 24.65
US$ 22.45
US$ 22.74
US$ 21.73
US$ 29.24
US$ 23.00
US$ 24.79
US$ 24.35
